Comparing the current results to its competitors, Mirum Pharmaceuticals Inc reported Revenue increase in the 1 quarter 2026 by 43.28 % year on year. The sales growth was above Mirum Pharmaceuticals Inc 's competitors' average revenue growth of 15 %, achieved in the same quarter.
Mirum Pharmaceuticals Inc , slower than the average decrease reported by the company's competitors of -26.62 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -26.62 %
Mirum Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company competes with academic institutions, government agencies, research institutions, and biotechnology and pharmaceutical companies with greater resources and expertise. Notable competitors include GlaxoSmithKline plc and Ipsen Pharma, both developing therapies targeting sBA levels via the IBAT pathway. Ipsen has received approval for odevixibat (Bylvay) to treat pruritus in patients with PFIC and ALGS in the U.S. and EU. Additional competitors include Alfasigma S.p. (formerly Intercept Pharmaceuticals, Inc.) with Ocaliva; Gilead Sciences with Livdelzi and bulevirtide; and Leadiant Biosciences, which may be conducting clinical studies in CTX. Vir Biotechnology is developing tobevibart in combination with elebsiran for chronic HDV. Currently, there are no FDA-approved treatments competing with Cholbam in the U.S., although other cholic acid products are approved outside the U.S. and by the EMA. Other competitors referenced in filings include Laboratoires CTRS and Lonza.
Strong sales growth of 43.28 % in Overall company contributed to Mirum Pharmaceuticals Inc increase in total revenue by 43.28 % Mirum Pharmaceuticals Inc improved its market share in this segment, to approximately 0.17 %.
June 1, 2024
Mirum Pharmaceuticals Receives Positive CHMP Opinion for LIVMARLI (Maralixibat) Oral Solution in Treating Progressive Familial Intrahepatic Cholestasis in Patients as Young as Three Months Foster City, California, USA A Landmark Achievement in Pediatric HepatologyMirum Pharmaceuticals, Inc., listed on NASDAQ under the ticker MIRM, has announced a significant milestone for its innovative treatment, LIVMARLI (Maralixibat) oral solution. The European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending LIVMARLI for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) in patients aged three months and older. Positive CHMP Opinion: A Prelude to Wides...
May 31, 2024
Recent advancements in the field of pharmaceutical sciences have led to numerous breakthroughs in the treatment of various medical conditions. In this regard, Mirum Pharmaceuticals, a leading pharmaceutical company, has recently received positive news from the Committee for Medicinal Products for Human Use (CHMP) concerning their oral solution, LIVMARLI (maralixibat). The CHMP has granted a positive opinion for the use of LIVMARLI in patients starting from three months of age for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC). This article aims to delve deeper into the significance of this positive CHMP opinion and shed light on the impact it will have on the treatment landscape for PF...
Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Sources:
Mirum Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Mirum Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
